Nuvaring (Ethinylestradiol, Etonogestrel)

Ethinylestradiol and etonogestrel, the active ingredient in NuvaRing, is a combined estrogen‑progestogen contraceptive presented as a 0.015 mg/day ethinylestradiol and 0.12 mg/day etonogestrel vaginal ring for vaginal use. It prevents pregnancy in women of reproductive age by providing continuous hormone delivery throughout a three‑week cycle.

GNH USA supplies NuvaRing as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality, regulatory compliance, and reliable supply for global contraceptive programs.

NuvaRing, a combined estrogen‑progestogen contraceptive, is indicated for hormonal contraception.

Prevention of pregnancy: provides effective reversible contraception for women of reproductive age. Hormonal birth control: delivers continuous estrogen and progestogen to suppress ovulation. Cycle regulation: helps maintain a predictable menstrual cycle while preventing conception.

NuvaRing may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate headache episodes. - Nausea: occasional nausea or stomach upset. - Vaginal irritation: discharge, itching or discomfort at the insertion site. - Breast tenderness: mild swelling or tenderness of the breasts.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Hepatic dysfunction: jaundice or abnormal liver enzymes. - Allergic reaction: rash, swelling, or anaphylaxis.

Before prescribing NuvaRing, clinicians should consider several safety and handling precautions. - Smoking status: avoid use in women who smoke cigarettes and are over 35 years old. - Cardiovascular risk: assess history of hypertension, stroke, or myocardial infarction. - Migraine history: contraindicated in patients with migraine with aura. - Liver disease: use with caution in severe hepatic impairment. - Medication adherence: ensure correct insertion and removal schedule to maintain efficacy. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and direct sunlight.

NuvaRing can interact with other medicines, altering its contraceptive effectiveness or increasing adverse event risk.

Major Interactions (Avoid): - Enzyme inducers: carbamazepine, phenytoin, rifampicin may reduce hormone levels. - Antifungal azoles: ketoconazole can increase hormone concentrations, raising side‑effect risk. - Certain antibiotics: long‑term use of rifampin may compromise contraceptive efficacy.

Moderate Interactions (Monitor Closely): - Antidepressants: sertraline may slightly affect hormone metabolism. - Antihypertensives: beta‑blockers may have additive effects on blood pressure.